AstraZeneca Asserts New Patent In Pulmicort Suit

Law360, New York (May 11, 2009, 12:00 AM EDT) -- AstraZeneca Pharmaceuticals LP has asserted a new patent in its suit to prevent Apotex Inc. from launching a generic version of Pulmicort Respules, AstraZeneca’s successful asthma treatment for children.

The amended complaint, filed Friday in the U.S. District Court for the District of New Jersey, adds a patent related to sterilizing the powdered form of a type of steroid for use in the treatment of allergic or inflammatory conditions of the nose or lungs.

U.S. Patent Number 7,524,834, title “Sterile powders, formulations and methods for producing...
To view the full article, register now.